Y-27632 dihydrochloride: Selective ROCK Inhibition for Advanced Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC50 values of 140 nM and Ki of 300 nM, respectively, and exhibits >200-fold selectivity over other kinases such as PKC and MLCK (ApexBio). It effectively inhibits Rho-mediated stress fiber formation and modulates cell cycle progression from G1 to S phase (Liu et al., 2023). The compound is widely used in stem cell viability enhancement, cancer invasion, and organoid modeling (uo126.com). Y-27632 demonstrates robust solubility in DMSO, ethanol, and water, with recommended storage at ≤4°C in desiccated conditions (ApexBio). Research confirms its capacity to reduce smooth muscle proliferation in vitro and suppress tumor invasion and metastasis in vivo (Liu et al., 2023).

Biological Rationale

Y-27632 dihydrochloride is designed to selectively inhibit Rho-associated protein kinases (ROCK1 and ROCK2). These kinases regulate actin cytoskeleton organization, cell shape, and motility. Inhibition of ROCK1/2 disrupts the formation of actin stress fibers and focal adhesions. This pathway is central to the regulation of cell proliferation, apoptosis, and migration (Liu et al., 2023). The Rho/ROCK axis is also implicated in stem cell self-renewal and differentiation. Modulation of this pathway is critical in cancer biology, tissue engineering, and regenerative medicine. ROCK inhibitors like Y-27632 provide a tool for dissecting cytoskeletal dynamics and evaluating cell cycle checkpoints. They are especially valuable in organoid and stem cell cultures, where cell viability and clonogenicity are sensitive to cytoskeletal tension (uo126.com).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds to the ATP-binding site of the catalytic domains of ROCK1 and ROCK2, inhibiting their kinase activity (ApexBio). This inhibition prevents phosphorylation of downstream targets such as myosin light chain (MLC), LIM kinase, and cofilin. The suppression of MLC phosphorylation leads to reduced actomyosin contractility. As a result, cells treated with Y-27632 display decreased stress fiber formation, altered focal adhesion dynamics, and disrupted cytokinesis. The compound exhibits an IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2, with minimal activity against PKC, MLCK, PAK, and cAMP-dependent protein kinase at concentrations up to 30 μM, demonstrating >200-fold selectivity (cpi-613.com). It is cell-permeable and rapidly reaches effective intracellular concentrations.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC50 of 140 nM in kinase assays (ApexBio, product page).
• Y-27632 reduces prostatic smooth muscle cell proliferation in vitro in a concentration-dependent manner (Liu et al. 2023, DOI).
• Solubility benchmarks: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C (ApexBio, product page).
• In vivo, Y-27632 diminishes pathological structures and reduces tumor invasion/metastasis in mouse models (Liu et al. 2023, DOI).
• Y-27632 enhances survival and expansion of stem cells and organoids, reducing apoptosis upon dissociation (Y-27632 Dihydrochloride: Advanced ROCK Inhibition, uo126.com).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used to modulate the Rho/ROCK signaling pathway in studies of cytoskeletal dynamics, cell migration, and invasion. It is a standard additive in stem cell culture protocols to promote viability, especially during passaging and clonal expansion. The compound is also applied in cancer research to inhibit tumor invasion and metastasis in vitro and in vivo. In organoid research, Y-27632 supports the survival of dissociated cells, facilitating efficient organoid establishment (Liu et al., 2023). For a discussion on its translational and next-generation applications, see Beyond Inhibition: Strategic Application of Y-27632 Dihydrochloride, which expands on the mechanistic and therapeutic scope beyond standard cytoskeletal studies.

Common Pitfalls or Misconceptions

• Y-27632 is not effective against non-ROCK kinases at standard working concentrations; it lacks significant activity against PKC, MLCK, and PAK (>200-fold selectivity).
• Prolonged exposure or high concentrations can induce off-target effects; dosing should be optimized for each system.
• Y-27632 does not inherently induce pluripotency or differentiation; it preserves viability during cell dissociation or stress.
• It is not a substitute for growth factors or niche signals in organoid or stem cell cultures.
• Long-term storage of Y-27632 solutions is not recommended due to potential degradation; freshly prepared aliquots are advised.

For further clarification on best practices and advanced workflow integration, our article Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibition for... provides atomic benchmarks and troubleshooting guidance, complementing this overview by emphasizing method optimization for reproducible Rho/ROCK pathway inhibition.

Workflow Integration & Parameters

Preparation: Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. Stock solutions may be prepared in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL) at 25°C. Solubility can be enhanced by warming to 37°C or using ultrasonic bath treatment (ApexBio).

Storage: Stock solutions are stable for several months when stored at <-20°C. Avoid repeated freeze-thaw cycles. Long-term storage of working dilutions is discouraged.

Usage: Typical working concentrations range from 5–20 μM for in vitro cell culture assays. For organoid or stem cell applications, 10 μM is a common starting point. For in vivo studies, dosing regimens should be validated for target tissue distribution and pharmacokinetics (sybr-green-i-for-real-time-pcr-100x.com). For a detailed analysis of translational parameters, see Y-27632 Dihydrochloride: Precision ROCK Inhibition for Translational Research, which contextualizes practical workflows in advanced disease modeling and cell mechanics.

Conclusion & Outlook

Y-27632 dihydrochloride (A3008) is a reference compound for precise, selective inhibition of ROCK1/2 kinases in research settings. Its robust solubility, high selectivity, and reproducible action across cytoskeletal, cancer, and stem cell applications make it indispensable for Rho/ROCK pathway studies (Liu et al., 2023). Ongoing research will further define its translational utility in tissue engineering, disease modeling, and regenerative therapy. For sourcing and technical details, refer to the Y-27632 dihydrochloride product page.